Researchers are evaluating whether circulating tumor DNA (ctDNA) tests, specifically Signatera, can safely reduce aggressive treatments for older women with ER-positive breast cancer. By detecting molecular residual disease, clinicians aim to avoid unnecessary chemotherapy or extensive surgery in patients whose blood tests show no remaining cancer cells.
For decades, the standard of care for estrogen receptor-positive (ER+) breast cancer has been a “one size fits all” approach based on tumor size and node involvement. However, for older populations, the toxicity of chemotherapy can often outweigh the marginal survival benefit. The emergence of “dynamic biomarkers”—indicators that change over the course of treatment—allows us to move from static staging to real-time molecular surveillance.
In Plain English: The Clinical Takeaway
- Less Toxicity: Some older patients may be able to skip chemotherapy if a blood test proves the cancer is completely gone.
- Precision Monitoring: Instead of waiting for a scan to show a tumor, ctDNA can detect “molecular” relapse much earlier.
- Personalized Surgery: Doctors are investigating if a negative blood test means a less invasive surgical approach is safe.
The Mechanism of Action: How ctDNA Detects “Invisible” Cancer
Circulating tumor DNA (ctDNA) consists of small fragments of DNA shed by cancer cells into the bloodstream. In ER+ breast cancer, the goal is to identify Minimal Residual Disease (MRD)—the small number of cancer cells that remain in the body after primary treatment but are too few to be seen on a PET scan or MRI.
The Signatera platform utilizes a “tumor-informed” approach. This means the test is personalized; clinicians first sequence the patient’s actual tumor to identify unique genetic mutations. They then create a custom “molecular fingerprint” to search for those specific mutations in the blood. This increases sensitivity and reduces the likelihood of false positives compared to generic assays.
The clinical objective here is treatment de-escalation. If a patient is ctDNA-negative after initial therapy, the statistical probability of recurrence is significantly lower, potentially allowing the physician to omit adjuvant chemotherapy (chemotherapy given after the primary treatment) without compromising the patient’s long-term prognosis.
Global Access and Regulatory Landscapes
The implementation of ctDNA-guided decisions varies significantly by geography. In the United States, the FDA has cleared various liquid biopsy tests, but reimbursement remains a hurdle. Many private insurers require extensive evidence of “clinical utility”—proof that the test actually changes the outcome—before covering the cost.
In Europe, the European Medicines Agency (EMA) and national bodies like the NHS in the UK are more cautious, often restricting these tests to clinical trial settings until large-scale, randomized controlled trials (RCTs) prove that de-escalation does not lead to higher mortality rates. For the average patient in the UK or EU, access currently depends on enrollment in academic research protocols.
The funding for these advancements is largely driven by a mix of public grants (such as the NIH) and private biotechnology firms. It is critical to note that companies producing these tests have a vested interest in their adoption; independent validation by non-industry-funded academic centers is the gold standard for establishing trust.
“The transition from anatomical staging to molecular monitoring represents a paradigm shift. We are no longer asking ‘Is the tumor gone?’ but ‘Is the signal gone?’ This distinction is where the potential for reducing over-treatment lies.”
Comparing ctDNA to Traditional Surveillance
To understand the impact of this technology, we must compare it to the current standard of care, which relies on physical exams and periodic imaging.
| Feature | Standard Imaging (CT/MRI/Mammo) | ctDNA (Tumor-Informed) |
|---|---|---|
| Detection Threshold | Requires a visible mass (millions of cells) | Can detect a few fragments of DNA |
| Timing | Scheduled intervals (e.g., every 6 months) | Can be tested more frequently/dynamically |
| Invasiveness | Non-invasive (imaging) or biopsy | Minimally invasive (blood draw) |
| Primary Use | Localization and sizing of tumor | Detection of MRD and recurrence risk |
The Challenge of “Molecular Relapse”
A significant clinical dilemma arises when a patient is “molecularly positive” but “radiologically negative.” This means the blood test detects cancer DNA, but the scans show nothing. This is known as lead-time advantage.
Although this allows for earlier intervention, it creates a psychological burden for the patient and a therapeutic challenge for the doctor. If there is no visible target to treat, does the physician start chemotherapy based on a blood test alone? Current consensus suggests that ctDNA should be used as a tool to increase surveillance rather than as a sole trigger for aggressive systemic therapy, unless the patient is part of a controlled clinical trial.
Epidemiological data from the National Cancer Institute indicates that for women over 70, the risks of chemotherapy—such as neutropenia (dangerously low white blood cell count) and cardiac toxicity—can be severe. The “benefit-to-risk ratio” is much tighter in this demographic, making de-escalation a public health priority.
Contraindications & When to Consult a Doctor
ctDNA testing is not appropriate for all patients. It is generally not indicated for patients with particularly low-grade, indolent tumors where the risk of recurrence is already negligible, or for those who are medically unfit for any form of systemic therapy regardless of the test result.
Patients should consult their oncologist immediately if they experience “red flag” symptoms despite a negative ctDNA result, including:
- New, unexplained lumps in the breast or axillary (underarm) area.
- Persistent bone pain or unexplained weight loss.
- Shortness of breath or chronic cough (potential signs of distant metastasis).
Note: A negative ctDNA test is not a guarantee of cancer eradication; it is a risk-stratification tool and must be used in conjunction with clinical exams.
The Path Toward Precision Oncology
The move toward ctDNA-guided treatment represents a shift toward “precision oncology.” By integrating genetic sequencing with clinical data, we can move away from the toxicity of broad-spectrum chemotherapy for those who do not necessitate it, while intensifying treatment for those whose molecular signals suggest a high risk of relapse.
As we move further into 2026, the focus will shift from “can we detect it” to “how do we act on it.” The goal is a future where breast cancer treatment is as unique as the patient’s own DNA, ensuring that older adults maintain their quality of life without sacrificing their survival.
